Aug 7, 2019

Life Science Institute obtains a license for manufacturing of regenerative medicine products

Life Science Institute, Inc.

Life Science Institute, Inc. (LSII; Head office: Chiyoda-ku, Tokyo; President: Seiichi Kiso) is pleased to announce that LSII has obtained a license for manufacturing of regenerative medicine products at a Cell Processing Center (Tonomachi CPC) for Muse cell-based product.

As previously announced, LSII established Tonomachi CPC, a cell processing center for Muse cell-based product, in October 2018. Then, LSII obtained a license for marketing of regenerative medicine products in April 2018, and secured a manufacturing of regenerative medicine products at Tonomachi CPC in July 2018.

Currently, clinical trials of Muse cell-based product are in progress for four indications (acute myocardial infarction, ischemic stroke, epidermolysis bullosa and spinal cord injury) and LSII plans to submit an application for marketing approval for Muse cell-based product to the Pharmaceuticals and Medical Devices Agency, or PMDA of Japan in FY2020.

Seiichi Kiso, LSII President, commented, "We are preparing to provide Muse cell-based product to patients as soon as possible. I hope we will be able to propose a new treatment option for patients with these diseases for which there is no effective therapy and contribute to improving their quality of life."

About Life Science Institute, Inc.
Founded in 2014, Life Science Institute, Inc. promotes business in three healthcare domains: health and medical ICT business, next generation healthcare, and drug discovery solutions. By offering diverse solutions to people hoping for good health, such as a solution to meet patients' unmet medical needs, it aims to realize KAITEKI in which people can lead healthy and comfortable lives. The consolidated net sales of Life Science Institute, Inc. in FY2018 131.8 billion yen.
For further information, please visit
www.lsii.co.jp/